Tenaya Therapeutics sees advances in symptom relief and cardiac hypertrophy measures

Tenaya Therapeutics sees advances in symptom relief and cardiac hypertrophy measures
Tenaya Therapeutics trial shows promise

Tenaya Therapeutics has released new interim results from its ongoing clinical trial of TN-201, pointing to promising improvements in patient symptoms, functional capacity, and measures of cardiac hypertrophy.

The company noted the data support continued evaluation of the investigational therapy for potential use in treating cardiac conditions. Additional details can be found on the company website as Tenaya Therapeutics advances its clinical research in the field.

Tenaya Therapeutics CEO Faraz Ali is scheduled to present at the Jefferies Global Healthcare Conference on June 4. Earlier this year, the company honored Eugene Braunwald for his work in hypertrophic cardiomyopathy and modern cardiology at a dedicated event. These developments reflect Tenaya’s continued engagement with the cardiology research community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.